0 Ratings
ID

45234

Description

Principal Investigator: Dawood Darbar, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA MeSH: Atrial Fibrillation https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000439 The goal of this study was to identify genetic predictors of response to rate control therapy in patients with AF. We conducted a genome-wide association study (GWAS) focusing on subjects with a history of atrial fibrillation. Rate control therapy for AF uses a range of drugs (beta-adrenergic receptor blockers, calcium channel blockers, and digitalis) to depress conduction through the AV node, thereby preventing rapid rates and minimizing symptoms. In large groups of patients, such as the Vanderbilt AF Registry (a clinical and genetic repository with over 1200 patients with ECG-confirmed AF) from which these study subjects were drawn, approximately 5% display failure of aggressive AV nodal-blocking therapy to control ventricular rate. In these patients, interruption of the AV node by ablation and pacemaker implantation are necessary for adequate rate control. Study cases were individuals who underwent AV node ablation and pacemaker implantation after combined therapy with 3 AV nodal-blocking agents was ineffective in rate control. Controls for this study were individuals who met standardized rate-control efficacy criteria (as described in AFFIRM study, Wyse et al, NEJM 2002; PMID: 12466506) for optimal rate control with 2 or fewer AV nodal-blocking agents. Two additional groups were genotyped by RIKEN: An additional group of patients with AF as well as subjects undergoing cardiac surgery in whom AF did not occur post-operatively. All study participants were recruited and treated/evaluated at Vanderbilt University Medical Center. This study was conducted by the Pharmacogenomics of Arrhythmia Therapy subgroup of the Pharmacogenetics Research Network, a nationwide collaboration of scientists studying the genetic contributions to drug response variability. Genotyping was performed by the RIKEN research institute in Japan using the Illumina 610 Quad Beadchip platform.

Link

dbGaP study = phs000439

Keywords

Versions (2)
  1. 7/21/22 7/21/22 - Simon Heim
  2. 10/12/22 10/12/22 - Adrian Schulz
Copyright Holder

Dawood Darbar, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA

Uploaded on

October 12, 2022

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

  • Newest
  • Oldest
  • Popular
  • Newest
    • Newest
    • Oldest
    • Popular

    No comments

    In order to download data models you must be logged in. Please log in or register for free.

    dbGaP phs000439 PGRN-RIKEN: Rate Control Therapy in Patients with Atrial Fibrillation

    English

    Eligibility Criteria

    4 forms  
    Inclusion and exclusion criteria
    Description

    Inclusion and exclusion criteria

    Inclusion criteria for all AF subjects: Must be between 18 and 100 years old with a diagnosis of atrial fibrillation. Additionally, subject must have a family member with known AF.
    Description

    Inclusion criteria for all AF subjects: Must be between 18 and 100 years old with a diagnosis of atrial fibrillation. Additionally, subject must have a family member with known AF.

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C1512693
    UMLS CUI [1,2]
    C1706256
    UMLS CUI [1,3]
    C0004238
    UMLS CUI [1,4]
    C0001779
    UMLS CUI [1,5]
    C0086282
    UMLS CUI [1,6]
    C0004238
    Exclusion criteria for all AF subjects: New onset AF occurring within 3 months of CABG or valve surgery; AF occurring post heart transplant; Post allogeneic bone marrow transplant.
    Description

    Exclusion criteria for all AF subjects: New onset AF occurring within 3 months of CABG or valve surgery; AF occurring post heart transplant; Post allogeneic bone marrow transplant.

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0680251
    UMLS CUI [1,2]
    C1706256
    UMLS CUI [1,3]
    C0004238
    UMLS CUI [1,4]
    C1442461
    UMLS CUI [1,5]
    C0010055
    UMLS CUI [1,6]
    C2066019
    UMLS CUI [2,1]
    C0680251
    UMLS CUI [2,2]
    C1706256
    UMLS CUI [2,3]
    C0231290
    UMLS CUI [2,4]
    C0018823
    UMLS CUI [3,1]
    C0680251
    UMLS CUI [3,2]
    C1706256
    UMLS CUI [3,3]
    C0231290
    UMLS CUI [3,4]
    C0194037
    Controls were defined as those subjects who satisfied the following criteria (AFFIRM) after treatment with 2 or fewer AV nodal-blocking agents: average heart rate (HR) ≤ 80 bpm at rest, in addition to either an average 24-hour HR ≤ 100 bpm and no maximal 24-hr HR > 110% of the predicted age-adjusted maximum exercise HR, or a HR ≤ 110 bpm during a 6-minute walk test.
    Description

    Controls were defined as those subjects who satisfied the following criteria (AFFIRM) after treatment with 2 or fewer AV nodal-blocking agents: average heart rate (HR) ≤ 80 bpm at rest, in addition to either an average 24-hour HR ≤ 100 bpm and no maximal 24-hr HR > 110% of the predicted age-adjusted maximum exercise HR, or a HR ≤ 110 bpm during a 6-minute walk test.

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C1512693
    UMLS CUI [1,2]
    C0009932
    UMLS CUI [1,3]
    C0087111
    UMLS CUI [1,4]
    C0013227
    UMLS CUI [1,5]
    C4523943
    UMLS CUI [1,6]
    C0018810
    Cases were defined as those subjects who failed to satisfy the AFFIRM criteria after combined therapy with 3 AV nodal-blocking agents and required AV node ablation and pacemaker implantation.
    Description

    Cases were defined as those subjects who failed to satisfy the AFFIRM criteria after combined therapy with 3 AV nodal-blocking agents and required AV node ablation and pacemaker implantation.

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C1706256
    UMLS CUI [1,2]
    C0087111
    UMLS CUI [1,3]
    C0013227
    UMLS CUI [1,4]
    C4523943
    UMLS CUI [1,5]
    C1514873
    UMLS CUI [1,6]
    C3275044
    UMLS CUI [1,7]
    C0189863
    Criteria for post-op patients with no AF: All adult patients scheduled for elective cardiothoracic surgery who are capable of providing informed consent will be eligible for the study. Emergency patients or hemodynamically unstable patients for whom discussion of consent would delay surgery or who are incapable of providing consent will be excluded.
    Description

    Criteria for post-op patients with no AF: All adult patients scheduled for elective cardiothoracic surgery who are capable of providing informed consent will be eligible for the study. Emergency patients or hemodynamically unstable patients for whom discussion of consent would delay surgery or who are incapable of providing consent will be excluded.

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C1512693
    UMLS CUI [1,2]
    C1549444
    UMLS CUI [1,3]
    C0004238
    UMLS CUI [1,4]
    C2242990
    UMLS CUI [1,5]
    C0085732
    UMLS CUI [1,6]
    C0021430
    UMLS CUI [2,1]
    C0680251
    UMLS CUI [2,2]
    C0021430
    UMLS CUI [2,3]
    C1640361
    UMLS CUI [2,4]
    C0543467
    Back to the top of the page

    Similar models

    Eligibility Criteria

    4 forms
    Name
    Type
    Description | Question | Decode (Coded Value)
    Data type
    Alias
    Item Group
    Inclusion and exclusion criteria
    Inclusion criteria for all AF subjects: Must be between 18 and 100 years old with a diagnosis of atrial fibrillation. Additionally, subject must have a family member with known AF.
    Item
    Inclusion criteria for all AF subjects: Must be between 18 and 100 years old with a diagnosis of atrial fibrillation. Additionally, subject must have a family member with known AF.
    boolean
    C1512693 (UMLS CUI [1,1])
    C1706256 (UMLS CUI [1,2])
    C0004238 (UMLS CUI [1,3])
    C0001779 (UMLS CUI [1,4])
    C0086282 (UMLS CUI [1,5])
    C0004238 (UMLS CUI [1,6])
    Exclusion criteria for all AF subjects: New onset AF occurring within 3 months of CABG or valve surgery; AF occurring post heart transplant; Post allogeneic bone marrow transplant.
    Item
    Exclusion criteria for all AF subjects: New onset AF occurring within 3 months of CABG or valve surgery; AF occurring post heart transplant; Post allogeneic bone marrow transplant.
    boolean
    C0680251 (UMLS CUI [1,1])
    C1706256 (UMLS CUI [1,2])
    C0004238 (UMLS CUI [1,3])
    C1442461 (UMLS CUI [1,4])
    C0010055 (UMLS CUI [1,5])
    C2066019 (UMLS CUI [1,6])
    C0680251 (UMLS CUI [2,1])
    C1706256 (UMLS CUI [2,2])
    C0231290 (UMLS CUI [2,3])
    C0018823 (UMLS CUI [2,4])
    C0680251 (UMLS CUI [3,1])
    C1706256 (UMLS CUI [3,2])
    C0231290 (UMLS CUI [3,3])
    C0194037 (UMLS CUI [3,4])
    Controls were defined as those subjects who satisfied the following criteria (AFFIRM) after treatment with 2 or fewer AV nodal-blocking agents: average heart rate (HR) ≤ 80 bpm at rest, in addition to either an average 24-hour HR ≤ 100 bpm and no maximal 24-hr HR > 110% of the predicted age-adjusted maximum exercise HR, or a HR ≤ 110 bpm during a 6-minute walk test.
    Item
    Controls were defined as those subjects who satisfied the following criteria (AFFIRM) after treatment with 2 or fewer AV nodal-blocking agents: average heart rate (HR) ≤ 80 bpm at rest, in addition to either an average 24-hour HR ≤ 100 bpm and no maximal 24-hr HR > 110% of the predicted age-adjusted maximum exercise HR, or a HR ≤ 110 bpm during a 6-minute walk test.
    boolean
    C1512693 (UMLS CUI [1,1])
    C0009932 (UMLS CUI [1,2])
    C0087111 (UMLS CUI [1,3])
    C0013227 (UMLS CUI [1,4])
    C4523943 (UMLS CUI [1,5])
    C0018810 (UMLS CUI [1,6])
    Cases were defined as those subjects who failed to satisfy the AFFIRM criteria after combined therapy with 3 AV nodal-blocking agents and required AV node ablation and pacemaker implantation.
    Item
    Cases were defined as those subjects who failed to satisfy the AFFIRM criteria after combined therapy with 3 AV nodal-blocking agents and required AV node ablation and pacemaker implantation.
    boolean
    C1706256 (UMLS CUI [1,1])
    C0087111 (UMLS CUI [1,2])
    C0013227 (UMLS CUI [1,3])
    C4523943 (UMLS CUI [1,4])
    C1514873 (UMLS CUI [1,5])
    C3275044 (UMLS CUI [1,6])
    C0189863 (UMLS CUI [1,7])
    Criteria for post-op patients with no AF: All adult patients scheduled for elective cardiothoracic surgery who are capable of providing informed consent will be eligible for the study. Emergency patients or hemodynamically unstable patients for whom discussion of consent would delay surgery or who are incapable of providing consent will be excluded.
    Item
    Criteria for post-op patients with no AF: All adult patients scheduled for elective cardiothoracic surgery who are capable of providing informed consent will be eligible for the study. Emergency patients or hemodynamically unstable patients for whom discussion of consent would delay surgery or who are incapable of providing consent will be excluded.
    boolean
    C1512693 (UMLS CUI [1,1])
    C1549444 (UMLS CUI [1,2])
    C0004238 (UMLS CUI [1,3])
    C2242990 (UMLS CUI [1,4])
    C0085732 (UMLS CUI [1,5])
    C0021430 (UMLS CUI [1,6])
    C0680251 (UMLS CUI [2,1])
    C0021430 (UMLS CUI [2,2])
    C1640361 (UMLS CUI [2,3])
    C0543467 (UMLS CUI [2,4])
    Back to the top of the page 

    Help

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial